| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
AZ-PFKFB3-26 is a potent and selective inhibitor of PFKFB3 with an IC50 of 23 nM. It also inhibits PFKFB1 and PFKFB2 with IC50 values of 2.06 µM and 0.384 µM, respectively. This selectivity for PFKFB3 over other isoforms makes it a valuable tool for studying the role of PFKFB3 in cancer metabolism.
|
|---|---|
| ln Vitro |
In vitro, AZ-PFKFB3-26 potently inhibits recombinant human PFKFB3 with an IC50 of 23 nM. It reduces levels of fructose-2,6-bisphosphate, the product of PFKFB3 activity. It shows selectivity over PFKFB1 (IC50 = 2.06 µM) and PFKFB2 (IC50 = 0.384 µM). These activities disrupt cancer cell metabolism and reduce cell proliferation.
|
| ln Vivo |
In vivo, AZ-PFKFB3-26 can be used in the study of non-small cell lung cancer. By inhibiting PFKFB3, it disrupts cancer cell metabolism and may reduce tumor growth. It has moderate lipophilicity, which may influence its pharmacokinetic properties. Detailed in vivo efficacy data are available in preclinical literature.
|
| Enzyme Assay |
In vitro enzyme assays for AZ-PFKFB3-26 typically involve measuring the inhibition of recombinant human PFKFB3, PFKFB1, and PFKFB2 enzymes. The enzyme is incubated with varying concentrations of the compound, and activity is measured by monitoring the production of fructose-2,6-bisphosphate or by coupled enzyme assays. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cell-based assays for AZ-PFKFB3-26 involve culturing cancer cell lines (e.g., non-small cell lung cancer cells) in appropriate media. Cells are treated with the compound at concentrations ranging from 0.01 µM to 10 µM for 24-72 hours. Cell viability is assessed by MTT or CellTiter-Glo assays. Metabolic flux and fructose-2,6-bisphosphate levels are measured. Apoptosis is evaluated by flow cytometry.
|
| Animal Protocol |
In vivo animal experiments for AZ-PFKFB3-26 typically involve administration to tumor-bearing mice via oral gavage or intraperitoneal injection. Tumor growth inhibition is monitored. Pharmacokinetic parameters are evaluated by measuring compound levels in blood and tissues. Target engagement is assessed by measuring fructose-2,6-bisphosphate levels in tumor tissues. Toxicity is assessed by monitoring body weight and organ histology.
|
| ADME/Pharmacokinetics |
As a small molecule (molecular weight ~400, formula C24H26N4O2), AZ-PFKFB3-26 has moderate lipophilicity. It is soluble in DMSO (40.25 mg/mL). Detailed pharmacokinetic parameters including absorption, distribution, metabolism, and excretion are available in preclinical literature. Oral bioavailability is expected based on its moderate lipophilicity.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data are specifically available for AZ-PFKFB3-26 from the search results. As a metabolic kinase inhibitor, potential toxicity may include effects on normal glucose metabolism. Comprehensive toxicological evaluation including acute, subchronic, and genotoxicity studies has likely been conducted in preclinical development. Standard laboratory safety precautions should be followed.
|
| Additional Infomation |
AZ-PFKFB3-26 (CAS#: 1704740-52-2) is a potent and selective PFKFB3 inhibitor (IC50 = 23 nM). It inhibits PFKFB1 (2.06 µM) and PFKFB2 (0.384 µM) with lower potency. It is studied for non-small cell lung cancer. Molecular weight ~400, formula C24H26N4O2.
|
| Molecular Formula |
C24H26N4O2
|
|---|---|
| Molecular Weight |
402.488845348358
|
| Exact Mass |
402.205
|
| CAS # |
1704740-52-2
|
| PubChem CID |
118735769
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
636
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)CN1C=C(C2=C1C=CC(=C2)OC3=CC=C(C=C3)NC(=O)[C@@H]4CCCN4)C#N
|
| InChi Key |
OOGHGWKBJXQNEJ-QFIPXVFZSA-N
|
| InChi Code |
InChI=1S/C24H26N4O2/c1-16(2)14-28-15-17(13-25)21-12-20(9-10-23(21)28)30-19-7-5-18(6-8-19)27-24(29)22-4-3-11-26-22/h5-10,12,15-16,22,26H,3-4,11,14H2,1-2H3,(H,27,29)/t22-/m0/s1
|
| Chemical Name |
(2S)-N-[4-[3-cyano-1-(2-methylpropyl)indol-5-yl]oxyphenyl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~12.42 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4845 mL | 12.4227 mL | 24.8453 mL | |
| 5 mM | 0.4969 mL | 2.4845 mL | 4.9691 mL | |
| 10 mM | 0.2485 mL | 1.2423 mL | 2.4845 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
